fbpx
X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

For Pandemic Surveillance, Labcorp Scientists Sequence Thousands of SARS-CoV-2 Samples with HiFi Reads

Wednesday, March 3, 2021

As new strains of the SARS-CoV-2 virus emerge—including variants that appear to make the virus more contagious or potentially more likely to effect the efficacy of the new vaccines—it’s clear that continued genomic surveillance will be essential as we try to rein in the COVID-19 pandemic.

Fortunately, scientists have been using all the tools at their disposal, including SMRT Sequencing platforms from PacBio. In a talk presented at a virtual American Society for Microbiology event in December 2020, Labcorp’s Michael Levandoski spoke about using the Sequel II System for mapping COVID-19 outbreaks by location and over time.

Watch Levandoski’s full presentation:

As a reference lab taking samples from all over the U.S., Labcorp has unique insight into the genetic path of the virus in the world’s largest outbreak. “The samples we collect represent circulating virus in the population,” Levandoski noted, adding that the company has tested more than 3.4 million positive samples as of February 2021. For each sample collected, metadata about timing, location, and patient demographics are recorded to create a truly valuable data set. The company’s large-scale SARS-CoV-2 sequencing project was built on a Sequel II System workflow, analyzing remnants of samples that have tested positive with diagnostic assays.

Of course, that means Labcorp scientists are working with low-input samples, for which they use two pools of overlapping 1.2 kb amplicons to sequence the whole viral genome at a pace of 600 to 1,000 genomes per SMRT Cell using HiFi reads. Levandoski’s team has sequenced more than 17,000 genomes as of February 26, 2021 and reports that HiFi assemblies offer very high resolution without missing any regions, so scientists can identify new mutations with confidence. “We’re able to detect new mutations and variants in the population as they appear,” he said. The team has nearly 20,000 archived samples collected from before March 15th that are in the pipeline for sequencing, and new samples will continue to be sequenced for pathogen surveillance purposes.

With such a small genome, though, is long-read sequencing really necessary? Levandoski thinks so: he told conference attendees that short-read amplicon sequencing could miss new mutations that are key to monitoring transmission and the outcome of vaccinations. By ensuring that all mutations are detected with highly accurate HiFi reads, his team can check each new genetic change to determine whether it’s in a clinically relevant region of the genome.

As a result of this ongoing surveillance work, Labcorp was awarded a sequencing surveillance contract with the US Centers for Disease Control as a part of their efforts to track and learn more about SARS-CoV-2 as it evolves and spreads throughout the country.

Download the Labcorp protocol and learn more about the benefits of using PacBio sequencing for SARS-CoV-2 surveillance.

Subscribe for blog updates:

Archives